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Background: Several new assays have been developed for high-risk HPV testing of cervical samples; we compare six HPV tests in a
screening population.
Methods: Residual material from liquid-based PreservCyt samples was assayed. Four tests (Hybrid Capture 2, Cobas, Abbott and
Becton-Dickinson (BD)) measured HPV DNA while two used RNA (APTIMA and NorChip).
Results: Positivity rates ranged from 13.4 to 16.3% for the DNA-based tests with a significantly lower positivity rate for the Abbott
assay. The Gen-Probe APTIMA assay was positive in 10.3% of women, which was significantly lower than all the DNA tests;
the NorChip PreTect HPV-Proofer test was much lower at 5.2%. 40 CIN2þ cases were identified, of which 19 were CIN3þ .
All CIN3þ cases were HPV positive by all tests except for one, which was negative by the Abbott assay and five which were
negative by the NorChip test.
Conclusion: All HPV tests except NorChip showed high sensitivity for high-grade lesions positive by cytology, suggesting
co-testing is unnecessary when using HPV tests. Positivity rates in cytology-negative specimens were similar for the DNA-based
tests, but lower for the APTIMA test suggesting this maintains the high sensitivity of DNA tests, but with better specificity.
There is widespread interest in introducing HPV testing for
primary screening and triage. Many studies have shown that HPV
DNA testing has higher sensitivity but lower specificity than
cytology (Cuzick et al, 2006, 2008a, Ronco et al, 2010). However,
there are limited comparisons between the different HPV tests. We
have previously carried out studies which have compared a number
of adjunctive tests in women with abnormal smears who have been
referred to colposcopy (Szarewski et al, 2008, Szarewski et al,
2012). These studies were focused primarily on identifying tests
with good sensitivity, and the specificities reflect the typically lower
values found in a referral setting. Although this approach does
permit a comparison of relative specificity, it is desirable to also
compare these tests in a screening setting. A definitive comparison
of sensitivity in this setting would require studies of at least 20 000
women, but specificity can be accurately evaluated in a much
smaller sample size. Here we compare four DNA-based HPV tests
and two RNA-based HPV tests in a screening setting.
MATERIALS AND METHODS
Residual material was used from the liquid-based cytology
PreservCyt samples from 6000 women who attended for a routine
3 or 5 yearly (depending on age) screening smear, and whose
samples were sent to the cytology laboratory at St. Mary’s Hospital,
London. Unsatisfactory cytology samples were excluded; there
were no other inclusion/exclusion criteria. Samples were linked to
concurrent cytology results and any histology within 6 months of
an abnormal smear, and this information was fully anonymised
before being transferred for analysis.
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Consent was deemed not to be necessary, as the women were
not going to be contacted with their result, nor would it be used to
influence their management. This also meant that we were
unable to access details of any previous screening history.
The study was approved by the Imperial NHS Trust Tissue
Management Committee and the Multicentre Research Ethics
Committee for Wales.
All results are presented based on the local histopathology and the
highest grade of abnormality seen in the biopsy or treatment
specimen was used. As the study was anonymised, the HPV result
was not communicated to the women or the doctor and was not
acted upon. This means that women who tested positive for HPV,
but had normal cytology would not have been further investigated,
and therefore disease ascertainment was not possible in this group. In
addition, it was not possible to undertake histology review. However,
our experience from previous studies (Szarewski et al, 2012) is that,
when pathology review is possible, 5% of biopsies read as CIN2þ
are downgraded tooCIN2; conversely, 6% of biopsies reported
asoCIN2 are upgraded to CIN2þ following pathology review.
Laboratory methods. In this study the following assays were
carried out and scored in strict accordance with the manufacturer’s
protocol. All tests were carried out in the Centre for Cancer
Prevention (by LH & GT), except for PreTect HPV-Proofer, which
was carried out at The Doctors Laboratory (SL), and the APTIMA
typing test (not the consensus test), which was performed in the
Gen-Probe laboratory (see below).
(a) DNA-based detection and genotyping assays:
 Hybrid Capture 2 (Qiagen GmbH, Hilden, Germany) detecting
13 HR-HPV genotypes collectively. The Hybrid Capture 2 assay
is based on the hybridisation of HPV DNA to a 13 HR HPV
RNA probe cocktail. The DNA:RNA hybrid is captured by an
antiDNA:RNA antibody and detected by chemiluminescence.
Readings over 1 RLU were considered positive.
 Cobas 4800 HPV test (Roche Molecular Diagnostics,
Pleasanton, CA, USA). The Cobas 4800 HPV test is a qualitative
in vitro test for the detection of 14 HR HPV types. The test
separately identifies HPV 16 and HPV 18, while concurrently
detecting the 12 remaining the high-risk types as a group (31, 33,
35, 39, 45, 51, 52, 56, 58, 59, 66 and 68).
 Abbott RealTime High Risk HPV assay (Abbott Molecular
GmbH & Co. KG, Wiesbaden, Germany). This qualitative
multiplex real-time test also separately identifies HPV 16 and
HPV 18 while concurrently detecting the 12 remaining high-risk
types as a group (31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68).
 BD HPV test (BD Diagnostics, Sparks, MD, USA). This is a real-
time PCR (at the time of writing, not yet commercially
available), which detects 14 HR HPV types. Type-specific
detection is achieved using sequence-specific (non-consensus)
E6/E7 DNA amplification. Typing is provided for types 16, 18,
31, 45, 51, 52 and 59. The remaining HPV types are grouped into
two pools: (33, 56, 58, 66) and (35, 39, 68).
(b) RNA-based detection assays
 PreTect HPV-Proofer (NorChip, Klokkarstua, Norway). PreTect
Proofer is a real-time multiplex NASBA assay for isothermal
amplification of E6/E7 mRNA expressed by five high-risk HPV
types (16, 18, 31, 33 and 45) using proprietary primer sets
(Molden et al, 2007).
 APTIMA (Gen-Probe Incorp, San Diego, CA, USA). The APTIMA
assay is based on target capture, transcription-mediated amplifica-
tion and hybridisation protection for the detection of E6/E7 mRNA
expression of 14 HR HPV types. Specimens which tested positive
by APTIMA were then tested with HPV type-specific tests, which
detected; Joo et al, 2010). On the basis of the same principle as
APTIMA HPV (AHPV) assay for the detection of HPVE6/E7
mRNA from 14 HR HPV genotypes, Gen-Probe has also developed
the APTIMA HPV 16 18/45 genotype (AHPV-GT) assay, which
specificially detects HPV 16, 18 and 45. The 95% detection limit for
these genotypes is 100 copies/reaction. The genotyping accuracy as
assessed by agreement with Linear Array genotyping test (Roche
Molecular) is 97% for HPV 16 and 93% for HPV18/45.
Statistical analysis. The main outcome measures were specificity
and positive predictive value (PPV) in women referred to
colposcopy based on cytology findings. Positivity cutpoints were
predefined for all tests. Relative sensitivity was also assessed as a
secondary end point. Confidence intervals for these were based on
binomial statistics. Comparisons between tests were conducted by
McNemar’s test for matched pairs; odds ratios and 95% confidence
intervals for discordant pairs of results are also reported. Additional
calculations of relative sensitivity, specificity and PPV were carried
out separately for women aged o30 and X30 years. Full details of
type-specific results will appear elsewhere, but positivity results for
HPV 16, HPV 18 and ‘other high-risk’ HPV are reported here.
The worst histology within 6 months of the initial baseline visit
was used as the outcome, and histologically confirmed CIN2þ and
CIN3þ were taken as the primary end points. Specificity is only
reported for oCIN2, as we do not consider the detection of CIN2 to
be a ‘false positive’. As this was an anonymised study, no pathology
review was possible (see Materials and Methods section above).
All statistical analyses were carried out using Stata 11.2
(StataCorp., College Station, TX, USA).
RESULTS
Residual ThinPrep samples from 6000 women attending for
routine (3–5 yearly) screening were assayed. The median age was
37 years (range 20–66, IQR 30–46) and 78% of the women were
aged 30 and above. A total of 5682 women (94.7%) had normal
cytology and were not referred for colposcopy. An additional 182
(3.0%) had borderline cytology and 35 of these (19%) were referred
for colposcopy of which 30 (86%) had a biopsy (Table 1). Most of
the women with mild dyskaryosis or worse had colposcopy (108
out of 136, 79.4%) and of these 89 out of 108 (82.4%) had a biopsy.
Positivity rates were in the range of 13.4–16.3% for the DNA-
based tests (Table 2). Positivity rates were generally higher among
women aged o30 years compared with women X30 years. For the
DNA-based tests, positivity ranged from 25.0 to 29.0% among
younger women (aged o30 years). Among women 30 years or
older, positivity rates for the DNA-based tests ranged from 10.0 to
12.6% (Supplementary Appendix Table A2). Results separately for
normal and abnormal cytology are also given in Supplementary
Appendix Table A2 by age.
The Gen-Probe APTIMA assay was positive in 10.3% of all
women and this was significantly lower than all the DNA tests
(Po0.0001 in all cases). The NorChip PreTect HPV-Proofer had a
significantly and substantially lower positivity rate than all other
tests, being 5.2%, which was equal to the positivity rate for
borderline or worse cytology.
Relative positivity rates for HPV 16 mirrored the findings for all
high-risk types (Table 2), being 2.8–3.5% for the three DNA tests
that provided typing and 2.1% for each of the RNA tests. HPV 18
positivity was lower, ranging from 0.9 to 1.4% and showed less
difference between tests, where the only significant difference was
Roche Cobas being higher than the RNA-based tests. Positivity for
only non 16/18 high-risk types showed similar patterns as for
all high-risk types, with the exception of NorChip PreTect
HPV-Proofer, which was much lower due, in part, to the restricted
number of HPV types tested (only 31, 33 and 45).
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There was a high concordance between the Roche Cobas, the
Abbott RealTime High Risk HPV assay and the BD assay, with
kappa values in excess of 0.8 for all pairwise comparisons (Table 3).
The Roche Cobas and BD tests had very similar performance, but
both were significantly more often positive than the Abbott
RealTime High Risk HPV assay, which was significantly less often
positive than all the other DNA tests. Kappa values for the HPV
DNA tests and Gen-Probe APTIMA were also high for type 16,
although Roche Cobas was more often positive than the other tests
for this type. Compared with all other tests, there was poorer
correlation with NorChip PreTect Proofer, which was less often
positive (Supplementary Appendix Table A3).
A total of 40 CIN2þ cases were identified, of which 19 were
CIN3þ . Of these, 5 of the CIN2 and 11 of the CIN3þ cases were
aged 30 or above. All of the CIN3þ cases were HPV positive by all
tests, except for the NorChip assay and one case, from a woman
aged 29 years, which was missed by the Abbott RealTime High
Risk HPV assay. Five CIN3þ cases were negative by the NorChip
Test, and three cases had an inadequate result for technical reasons
(Table 4 and Figure 1). Of the five cases with a negative result by
NorChip test, two were under the age of 30.
The CIN3þ case, in a woman aged 29, missed by the Abbott
assay was positive by Hybrid Capture 2 with an RLU of 85, and was
additionally typed by Linear Array (courtesy of Dr C Wheeler),
and showed strong bands for types 53, 66, 67, 70, 81, 82 and 84.
For the other tests it was generally a low-positive result for non
16/18 HPV types, and the BD assay was positive for the (33, 56,
58, 66) pool. Sensitivity for CIN2þ was again lower for the
NorChip test, but of the 21 cases of CIN2, all but one were positive
by all other tests, and the same case was negative throughout,
suggesting that the histology may have been inaccurate in this case.
As specificity for CIN3þ would treat CIN2 as a false positive,
which is inappropriate, we only report specificity for less than CIN2.
As seen from Table 4 and Figure 1, the tests with lower positivity
rates have higher specificity, with a 95.0% value for the NorChip test
90.2% for Gen-Probe, 87.2% for the Abbott assay and the three other
DNA tests ranging from 84.3 to 85.4%. The sensitivity and
specificity are generally higher for women over 30 years compared
with women o30 years, although the relative performance of the
tests was similar (Supplementary Appendix Table A1).
PPVs for CIN2þ and CIN3þ are also shown in Table 4, both
for all women and only those referred for colposcopy. The former
are artificially low due to non-referral of all negative and most
borderline smears, while the latter is an accurate measure only for
women with mild dyskaryosis or high-grade cytologic abnormal-
ities. The relative order of the performance of the tests was similar
for PPV and specificity, with high PPVs seen for tests with high
specificity.
DISCUSSION
The main strength of this study is a head- to-head comparison of
six HPV tests in a screening population in which all women were
evaluated by all tests. No other such comparison exists and we are













BD HPV 5998 5965 970 (16.3) 168 (2.8) 71 (1.2) 834 (14.0)
Roche Cobas 5986 5979 959 (16.0) 211 (3.5) 86 (1.4) 801 (13.4)
Qiagen Hybrid Capture 2 5984 5984 906 (15.1) — — —
Abbott RealTime High Risk HPV 5994 5990 801 (13.4) 180 (3.0) 70 (1.2) 634 (10.6)
Gen-Probe APTIMA 6000 5995 620 (10.3) 128 (2.1) 63 (1.1)a —
NorChip PreTect HPV-Proofer 5969 5747b 297 (5.2) 116 (2.0) c 51 (0.9) c 139 (2.4)d
Abbreviations: HPV¼human papillomavirus; HR¼ high risk.
aTested HPV 18/45 combined.
bn¼ 76 U1A mRNA not detected, n¼ 132 testing failed for technical reasons, n¼ 10 failed quality control, n¼ 4 low U1A mRNA (indeterminate result).
cSamples were excluded if the overall result was inadequate.
dIncludes only types 31, 33 and 45.













Negative 5682 0 0 0 0 0 0 0 5682
Borderline
dyskaryosis
152 2 16 1 7 3 1 0 182
Mild dyskaryosis 42 1 22 1 25 9 5 0 105
Moderate
dyskaryosis
5 0 0 0 4 6 3 0 18
Severe dyskaryosis 0 0 0 0 0 3 9 1 13
Total 5881 3 38 2 36 21 18 1 6000
Abbreviations: CIN¼ cervical intraepithelial neoplasia; HPV¼human papillomavirus; LEEP¼ loop electrosurgical excision procedure.
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only aware of studies comparing two or at most three different
tests, usually against Hybrid Capture 2, that is, vs Gen-Probe
APTIMA (Monsenego et al, 2011, Wu et al, 2010), the
Abbott RealTime High Risk HPV assay (Carozzi et al, 2011,
Poljak et al, 2011) and Roche Cobas/Linear Array (Castle et al,
2011, Gage et al, 2012, Wright et al, 2012).
Our estimates of sensitivity refer only to the ‘relative sensitivity’
in women whose cytology results indicated a need for referral. In
most cases this was mild dyskaryosis or worse, so that any disease
in women with negative or borderline cytologic changes (regardless
of their HPV status) would not be detected. Only in the case where
different HPV tests had different sensitivities in women testing
Table 3. Summary of discordant results between different tests









BD HPV — 0.83 0.78 0.81 0.65 0.33
Roche Cobas (145, 134)a — 0.75 0.85 0.64 0.35
1.1 (0.8, 1.4)
Qiagen Hybrid Capture 2 (204, 141) (225, 174) — 0.78 0.68 0.35
1.4 (1.2, 1.8) 1.3 (1.1, 1.6)
Abbott RealTime High
Risk HPV
(227, 57) (194, 35) (216, 108) — 0.70 0.39
4.0 (3.0, 5.4) 5.5 (3.9, 8.2) 2.0 (1.6, 2.5)
Gen-Probe APTIMA (421, 70) (414, 77) (353, 68) (279, 97) — 0.45
6.0 (4.7, 7.9) 5.4 (4.2, 6.9) 5.2 (4.0, 6.8) 2.9 (2.3, 3.7)
NorChip PreTect
HPV-Proofer
(684, 61) (670, 54) (625, 63) (532, 65) (375, 82) —
11.2 (8.6, 14.8) 12.4 (9.4, 16.7) 9.9 (7.6, 13.1) 8.2 (6.3, 10.8) 4.6 (3.6, 5.9)
Number in top half of Table represent kappa values. Numbers in bottom half of Table give discordant pairs (column positive/row negative vs column negative/row positive) and OR (95% CI).
a145 Tested positive for BD HPV and negative for Roche Cobas, and 134 tested negative for BD HPV and positive for Roche Cobas.









PPV (%,only for those referred for
colposcopy) (95% CI)
BD HPV
CIN3þ 100.0 (82.4–100.0) 2.0 (1.2–3.0) 16.5 (10.3–24.6)
CIN2þ 97.5 (86.8–99.9) 84.3 (83.3–85.2) 4.0 (2.9–5.5) 33.9 (25.3–43.3)
Roche Cobas
CIN3þ 100.0 (82.4–100.0) 2.0 (1.2–3.1) 16.7 (10.3–24.8)
CIN2þ 97.5 (86.8–99.9) 84.5 (83.6–85.4) 4.1 (2.9–5.5) 34.2 (25.6–43.7)
Qiagen Hybrid Capture 2
CIN3þ 100.0 (82.4–100.0) 2.1 (1.3–3.3) 16.0 (9.9–23.8)
CIN2þ 97.5 (86.8–99.9) 85.4 (84.5–86.3) 4.3 (3.1–5.8) 32.8 (24.4–42.0)
Abbott RealTime High Risk HPV
CIN3þ 94.7 (74.0–99.9) 2.2 (1.3–3.5) 16.1 (9.8–24.2)
CIN2þ 95.0 (83.1–99.4) 87.2 (86.3–88.0) 4.7 (3.4–6.5) 33.9 (25.3–43.5)
Gen-Probe APTIMA
CIN3þ 100.0 (82.4–100.0) 3.1 (1.9–4.7) 17.4 (10.8–25.9)
CIN2þ 97.5 (86.8–99.9) 90.2 (89.5–91.0) 6.3 (4.5–8.5) 35.8 (26.8–45.5)
NorChip PreTect HPV-Proofera
CIN3þ 68.8 (41.3–89.0) 3.7 (1.9–6.5) 20.0 (10.4–33.0)
CIN2þ 71.4 (53.7–85.4) 95.2 (94.7–95.8) 8.4 (5.5–12.2) 45.5 (32.0–59.4)
Abbreviations: CI¼ confidence interval; HPV¼ human papillomavirus.
aBased on 16 cases of CIN3þ and 35 cases of CIN2þ .
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negative (or borderline) for cytology, which was not reflected in
those with positive cytology result, could this distort the relative
performance in terms of sensitivity.
As the vast majority of cytologically negative (or borderline)
smears will not be associated with high-grade disease pathologically,
the effect on not having full ascertainment in this group will only
have a small impact on specificity. Again, unless the detection of the
disease differs substantially by test (which is unlikely given the high
sensitivity of all tests when cytology was positive) this will have a
very small effect on the ‘relative’ specificities of the different tests.
The study confirms the relative ordering of the specificities for
these six tests seen previously in a referral population (Szarewski
et al, 2008, 2012), but now also in a screening context. In this
study, more than 75% of the women were aged 30 or above
(Supplementary Appendix Table A1), a group in which HPV
testing is currently recommended by many groups. The use of
HPV testing in younger women in currently debated and our
results are relevant to both groups. In addition, all of the tests
except the NorChip PreTect HPV-Proofer showed a very high
sensitivity for CIN2þ in the women referred for colposcopy due
to abnormal cytology. Due to the design of the study, we were not
able to assess sensitivity in those with negative cytology or
borderline changes. Ideally, outcomes would be evaluated at the
next screening round for those women testing HPV positive.
The NorChip test showed lower sensitivity and because of this it
is more suited to be a triage test to reduce the referral rate than as a
primary screening test, where those who are negative would not be
subject to short-term follow-up.
Of the highly sensitive tests, the Gen-Probe APTIMA assay was
the most specific, with B5% fewer ‘false positives’. On a relative
basis, this comes to about 15% fewer false positives than seen for
the other highly sensitive DNA tests. Again, specificity has to be
regarded as ‘relative’, as some of those HPV-positive women may
well have harboured a high-grade lesion, which was not detected
due to non-referral of women with negative or borderline cytology.
However, the impact of this on specificity is likely to be small, and
the impact on ‘relative specificity’ is even smaller, as most of these
cases are likely to be positive on all the sensitive HPV tests.
Meijer et al (2009) have provided criteria for validating new
HPV tests. Their work focussed on using a single population, while
our approach has been to establish sensitivity primarily in a referral
population and specificity primarily in a screening population. In
the referral population (Szarewski et al, 2012) we have established
that four tests (Roche Cobas, Gen-Probe APTIMA, Abbot
RealTime High Risk HPV assay and BD HPV assay) achieved
the required sensitivity and ‘specificity’ compared with Hybrid
Capture 2. Here we report further evidence that specificity is
achieved in a screening population, and sensitivity was virtually
100% in all cases for these four tests. A specificity that was 98% of
that of Hybrid Capture 2 in this setting (thus meeting the
guidelines) would require a specificity of 87.0% or higher, which all
tests satisfy. However, we acknowledge that there were not enough
cases of CIN2þ in the screening population to validate that the
lower 95% CI for sensitivity was greater than 95% of the sensitivity
achieved for Hybrid Capture 2 in this study—97.5%, (see Table 4).
Reproducibility of these tests has previously been established in
a range of other studies (Carozzi et al, 2005, Dockter et al, 2009,
LeBar et al, 2009, Carozzi et al, 2011, Heideman et al, 2011, Poljak
et al, 2012) but was not formally performed in this study.
CONCLUSIONS
In this evaluation of six HPV tests from residual liquid-based
screening cytology specimens, all tests except for NorChip showed
high sensitivity for high-grade lesions that were positive by
cytology, suggesting that they are suitable for primary screening
and that dual co-testing with cytology as well is unnecessary.
Positivity rates in cytology-negative specimens were similar for the
DNA-based tests, but were lower for the APTIMA test, suggesting
it can maintain the high sensitivity of the DNA tests, but with a
better specificity, so that fewer women would need triage tests or
short-term follow-up. However, a long-term low-risk period after a
negative test has yet to be demonstrated for APTIMA or any RNA-
based test, as has been shown for some of the DNA-based tests,
especially Hybrid Capture 2 (Dillner et al, 2008, Cuzick et al,
2008b, Mesher et al, 2010, Rijkaart et al, 2012). Direct demonstra-
tion of this is desirable to support its use in primary screening, The
NorChip test had lower sensitivity but higher specificity, suggesting
its role may be more in triage than primary screening.
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Figure 1. Summary graph of the sensitivity and specificity results for
the detection of (A) CIN2þ and (B) CIN3þ (with 95% CI).
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